Incepta Intern Paper
Incepta Intern Paper
Incepta Intern Paper
1. Introduction
Incepta Pharmaceuticals Ltd. is a leading pharmaceutical company in Bangladesh established
in the year 1999. The company has a very big manufacturing facility located at Savar, 35
kilometers away from the center of the capital city Dhaka. The company produces various
types of dosage forms which include tablets, capsules, oral liquids, ampoules, dry powder
vials, powder for suspension, nasal sprays, eye drops, creams, ointments, lotions, gels,
prefilled syringes, liquid filled hard gelatin capsules, lyophilized injections, human vaccine
etc. Since its inception, Incepta has been launching new and innovative products in order to
fulfill unmet demand of the medical community.
Since 1999, the name “Incepta” has been synonymous with trust and reliability inherent with
the word quality. Quality is ingrained with the work of the colleagues here and all their
values. They are dedicated to the delivery of quality healthcare throughout the nation. Their
business practices and processes are designed to achieve quality results that meet the
expectations of patients, customers, business partners, and regulators. Incepta has a relentless
passion for quality in everything they do.
Everyone in Incepta strives for continuous improvement in their performance measuring
results carefully and ensuring that respect for people are never compromised
1
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Figure 1: Quality
Figure 2: Teamwork
Figure 3: Performance
Figure 4: Community
Figure 5: Clients
2
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
3
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
4
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
5
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Several other first ever product, Celenta (Celecoxib), Rofenta (Rofecoxib) and
Omidon (Domperidone) followed in the footsteps of Osartil.
A total of 23 new generics with 35 presentations were launched this year. 4 of these
generics were first ever in Bangladesh.
By the end of 2000 Incepta was the number 31st company of the country.
There was massive restructuring throughout the company. Sales, Distribution,
Marketing Strategy Department, and Factory; all were reorganized.
A total of 18 new generics with 37 presentations were launched this year. 11 of these
generics were first ever in Bangladesh.
By the end of the year Incepta was ranked the 12th company of the country. The
company had a phenomenal growth of 448% over the previous year (IMS).
A total of 32 new generics with 49 presentations were launched. 14 of these generics
were first ever in Bangladesh.
Massive expansion project of the factory was envisioned. New office for the sales and
distribution operation was also taking shape.
The company registered an excellent growth of 55.85% over the previous year. By the
end of the year Incepta was ranked the 10th company of the country (IMS).
Incepta kept on introducing innovative and newer molecules to the local market. A
total of 32 new generics with 48 presentations were launched. 18 of these generics
were first ever in Bangladesh.
The new office (Dhanmondi) for the sales and distribution operation was inaugurated.
The company registered an excellent growth of 28.5% over the previous year (IMS).
By the end of the year Incepta was ranked the 8th company of the country (IMS).
A total of 17 new generics with 32 presentations have been launched. 6 of these
generics were first ever in Bangladesh.
The company maintained an excellent growth of 48.2% over the previous year (IMS).
The ranking went up again and the company was ranked the 5th largest company of
the country with the highest growth rate among the top five (IMS).
We thrived under challenge and excelled in venturing into unexplored grounds and
continued to satisfy our customers. Incepta was audited and accepted as a supplier for
6
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
UNICEF & UNDP. We started to supply life saving drugs to UNICEF from March,
2005.
A total of 27 new generics with 76 presentations were launched. 12 of these generics
were introduced first time ever in Bangladesh.
The company maintained an excellent growth of 34.8% over the previous year (IMS).
The company was ranked 3rd largest with the highest growth among the top five
(IMS).
By 2006 Incepta had positioned itself as an innovative research oriented and
knowledge based pharmaceutical company specializing in analysis, design and
development of new products.
Incepta successfully started overseas marketing operation from May 2006.
A total of 25 new generics with 82 presentations were launched. 9 of these generics
were first ever in Bangladesh.
The company maintained an excellent growth of 31.26% over the previous year
(IMS).
The company maintained the ranking of 3rd largest (IMS).
Incepta pioneered the introduction of biotech products (Human Insulin) and
lyophilized products (Pantoprazole injection) in the Bangladesh pharmaceutical
market. This was the first time a local pharmaceutical company produced such highly
sophisticated technology product in the country.
A total of 32 new generics with 82 presentations were launched. 4 of these generics
were first ever in Bangladesh.
Marketing, Sales, Distribution and Administration departments shifted to the fully
owned new office premises in Tejgaon, Dhaka. The international standard head office
of Incepta started operation in the new office premises on 1st October, 2007.
A marketing and sales team was setup in Myanmar headed by a country manager
from the Marketing Strategy Team to promote the 35 products registered with the
Myanmar FDA.
The company maintained a growth of 12.93% over the previous year (IMS).
The company held the 3rd largest ranking (IMS) among the companies.
7
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Continued investment in our core strength that is our manufacturing plant led to
recognition from European authorities and on January 11, 2008 Incepta attained
European "Certificate of GMP Compliance".
40 new products with 86 presentations were introduced of which 10 were first ever in
Bangladesh.
The plant received GMP certification (General formulations and Cephalosporins)
from Kenyan Ministry of Health on January 21, 2008.
Incepta was also awarded GMP (Cephalosporins) from Ethiopian Ministry of Health
on July 22, 2008.
Incepta registered 51 products in Mongolia on September 26, 2008 (As first
Bangladeshi Company).
Incepta registered 3 products in Georgia on October 13, 2008 (As first Bangladeshi
Company).
In 2008 significant number of products got registration in different countries. 19
products from Democratic Republic of Congo, 20 products from Sri Lanka, 22
products from Togo, 8 products from Hong Kong, 20 products from Mauritania, 6
products from Vietnam, 1 product in Cambodia.
The company maintained a growth of 12.10% over the previous year (IMS).
The company became the 2nd largest (IMS) among the companies operating in
Bangladesh.
Incepta started venturing in the field of human vaccines and hormonal products.
Construction of the Vaccine & Hormones facilities started on 1st January 2009 and
8th November 2009 respectively.
Incepta became the first Bangladeshi Company to get GMP Compliance Certificate
from Turkey (Tablets, Capsules and Lyophilized products) on January 08, 2009.
Incepta achieved GMP certification from the Ministry of Health, Yemen on May 25,
2009 (Sterile and Non-sterile products).
Incepta launched 51 new products in 2009. 4 of these were first ever in Bangladesh
pharmaceutical market.
The company maintained an excellent growth of 27.71% over the previous year
(IMS).
8
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
In 2012 the company has launched 52 products, 7 of which are first ever in Bangladesh
market.
In 2013 the company has launched 40 products, 7 of which are first ever in Bangladesh
market.
Up to June, 2014 the company has launched 9 products, 1 of which is first ever in Bangladesh
market.
9
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Beginning in 2000, Incepta has been launching new and innovative products at a faster pace than its
competitors.
Up to June 2014 it has already launched 390 generics with a total of 696 presentations. The company
produces a wide variety of dosage forms covering nearly all the major therapeutic classes.
During the last 14 years of operation Incepta launched as many as 139 new generics for the first time
ever in Bangladesh. High focus on quality and timely introduction of much needed essential
medications previously unavailable in the country has enabled Incepta to become the second largest
pharmaceutical company of the country.
10
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
2001 78 11 12th
2000 35 4 31st
11
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Administrative Department
Engineering
Sales Department
Distribution Department
Production Department
Warehouse
Production
Quality Assurance
Engineering
These departments are described in the upcoming section of this report.
12
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
3. Warehouse
The warehouse of Incepta is an enclosed building and protects the stored goods from
environmental influences. They are secured against fire by the design of the buildings and
technical facilities. They are secured against fire by the design of the buildings and technical
facilities. The fire brigade facility has access to enable appropriate firefighting. The locking
system of the stored goods ensures that the access to the building is controlled.
Our warehouse is equipped with four different storage conditions; a) 2 oC – 8oC, b) 8oC –
15oC, c) 15oC -25oC, and d) ambient condition. There is specific quarantine and sampling
areas with dedicated separate storage location for cephalosporin, and steroids. Temperature
sensing is equipped with remote sensor technology.
There are controlled rooms with HVAC for specific materials and the conditions are
monitored to confirm compliance with the requirements. Also there is retention sample room.
The materials are stored in the warehouse by pallet racking. The status of materials and
products is controlled by colored status sticker.
The transaction of materials is done according to "first in first out" system. Accounting and
storage is maintained through SAP.
The area of warehouse includes-
1. Dispensing booth
2. Storage area for
a. Raw materials
b. Finished products
c. Packaging materials
3. Quarantine area for
a. Raw materials
b. Finished products
13
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Quarantine area: After receiving of raw material they are stored first in the
quarantine area. If Q.C sampling and checking is approved then shifted to the store.
Product ready for marketing: After “pass” from the Q.A.D finished products are
shifted for marketing.
14
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
15
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
3.6. The duties of Ware House is sequentially- Raw Materials issue to production
Receiving of “Batch Manufacturing Record” (BMR) from Production
Returning the access materials to Warehouse & information entry in “Inventory software”
16
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
17
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
18
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
19
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
4. Production Departments
4.1. Solid Dosage forms
4.1.1. Tablets
Tablets are the solid preparations each containing a single dose of one or more active
ingredients and obtained by compressing uniform volume of particles.
According to British Pharmacopoeia, “Tablets are solid dosage forms circular in shape with
either flat or convex faces and prepared by the compression or compaction of suitably
prepared medicament by means the tablet machine”.
Tablets are intended for oral administration. Some are swallowed whole, some after being
chewed; some are dissolved or dispersed in water before being administered and some are
retained in the mouth where the active ingredient is liberated.
Being the most common, convenient and inexpensive dosage form, tablet formulation and
design is the most important consideration in solid dosage form production in the
pharmaceuticals, which may be described as the process whereby the formulator ensures that
the correct amount of drug in the right form is delivered at or over the proper time at the
proper rate and in the desired location, while having its chemical integrity protected to that
point.
20
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
¯ Blending
Blending
¯ ¯
Compression Direct Compression
¯
Coating of Uncoated Tablets
¯
Coated Tablets
21
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
4.1.1.2. Granulation
Granulation is the process in which the primary powder particles are made to adhere to form
larger, multiparticle entities called granules. In other words, granulation may be considered as
a size enlargement process during which small particles are formed into larger, are physically
strong agglomerates in which the original particles can still be identified.
The pharmaceutical granulations are used primarily to prepare material for tableting. Some
granulations are dispensed as packets or capsules.
The pharmaceutical granules typically have a size range between 0.2 to 4.0mm, depending on
their subsequent use.
22
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
¯
Dry mixing
¯
Wet mixing (in case of wet granulation) by addition of demineralized (DM) water or Maize
starch paste in Rapid Mixer Granulator (RMG) for a certain time period specified in the
Batch Production Record (BPR)
¯
Initial Phase drying in Fluid Bed Dryer (FBD)
¯
Milling in the Multimill
¯
Partial drying in FBD
¯
Milling in the Multimill
¯
Terminal/Final drying in the FBD
¯
Sieving in the Vibratory Sifter according to the required particle/granule size
¯
Measurement of Loss on Drying (LOD)
¯
Granules of desired size ready for blending.
Following the above process, 2 types of granules are produced in the four-granulation units of
the industry, which include;
23
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
¯
Dry mixing
¯
Compression of the powder mixture into a slug on a heavy-duty rotatory tablet machine or
passing of powder through two rollers to produce a sheet of material by the process of roller
compaction
¯
Milling in the Multimill
¯
Granules with desired size ready for blending.
24
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
4.1.1.2.2. Machines used in the Granulation unit for the purpose of Granulation
In each granulation unit, the following machines are present for granulation;
Table 3: Machines used in the Granulation unit for the purpose of Granulation
Multimill Milling -
Table 4: Common Problems That Arise During Granulation & Their Remedies
Problems Remedies
25
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
4.1.1.3. Blending
Blending is the process of mixing lubricants, glidants and colorants with the granules prior to
compression (in case of granules containing the active ingredient/s) or mixing of active
ingredient/s along with lubricants, glidants and colorants with the placebo granules (in case
of granules without the moisture sensitive active ingredient/s) prior to compression. So, the
process in often-called lubrication or remixing.
¯
Transfer of glidants into the blender by passing through a sieve of mesh size 20 & Colorants
through 200 mesh screen
¯
Blending of the ingredients in the Drum (30 rpm) or Double Cone Blender (16 or 22 rpm) for
2-3 minutes as specified in the Batch Production Record (BPR) for a certain product
¯
Transfer of lubricants into the blender by passing through a sieve of mesh size 20
¯
Blending with the other ingredients in the same manner as stated above for 1 minute
¯
Granules are ready for compression
26
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Again, for placebo granules without any active ingredient/s the following procedure is used
in the blending units of Incepta Pharmaceutical Limited;
Placebo granules in the Drum or Double Cone Blender
¯
Transfer of Active ingredients & Glidants into the blender by passing through a sieve of mesh
size 20 & Colorants through 200 mesh screen
¯
Blending of the ingredients in the Drum (30 rpm) or
Double Cone Blender (16 or 22 rpm) for 2-3 minutes as specified in the Batch Production
Record (BPR) for a certain product
¯
Transfer of lubricants into the blender by passing through a sieve of mesh size 20
¯
Blending with the other ingredients in the same manner for 1 minute
¯
Granules are ready for compression
4.1.1.3.2. Machines Used in the Blending Units for the Purpose of Blending
The following machines are used in the blending units for blending;
Table 5: Machines Used in the Blending Units for the Purpose of Blending
Name of the Machine Function Capacity Speed (rpm)
65 Kg (large)
Drum Blender Blending -
35Kg (small)
27
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
4.1.1.4. Compression
Compression can be defined as the technique of applying force or pressure to the granules or
powders (in case of direct compression) to produce tablets of desired shape and size with the
help of tablet press machine.
Two types of compressions are seen in the tablet press units of the factory; they are-
Direct Compression
¯
Transfer of granules in the hooper of tablet press machine by hand or auto powder/granules
loader
¯
Rising of upper punch & dropping of lower punch
¯
Filling of die cavity through feed frame
¯
Removal of extra granules by scrape off plate
¯
Coming down of upper punch for compression to produce tablet
¯
Raising of both upper & lower punches to certain extent
¯
Ejection of tablet with the help of takeout plate
28
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
¯
Mixing of the active ingredient/s along with excipients including lubricants & disintegrants
¯
Transfer of mixer in the hooper of tablet press machine by hand or auto powder loader
¯
Rising of upper punch & dropping of lower punch
¯
Filling of die cavity through feed frame
¯
Removal of extra granules by scrape off plate
¯
Coming down of upper punch for compression to produce tablet
¯
Raising of both upper & lower punches to certain extent
¯
Ejection of tablet with the help of takeout plate
¯
Conventional Uncoated Tablets of desired shape and size
4.1.1.4.3. Machines Used in the Tablet Press Unit for The Purpose of Compression
In each tablet press unit, the following machines are present;
29
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Table 6: Machines Used in the Tablet Press Unit for The Purpose of Compression
Name of the Machine Function
Capping
Chipping
Sticking
Weight variation
Mottling
Hardness problem
30
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
4.1.1.5. Coating
Tablet coating is the application of a coating composition to a moving bed of tablets with the
intention of conferring benefits and properties to the dosage form over the uncoated variety.
The distribution of the coating is accomplished by the movement of the tablets either
perpendicular (coating pan) or vertical (air suspension) to the application of the coating
composition.
There are three primary components involved in tablet coating. They are;
Tablet properties
Coating process
- Coating equipment
- Parameters of coating process
- Facility & ancillary equipment
- Automation in coating process
Coating composition
31
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Polymers
Plasticizers
Solvent system
Colorant
32
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
¯
Transfer of colorant/s containing solution (previously prepared with the help of a
homogenizer) into the coating solution manufacturing vessel & mixing with the polymeric
solution
¯
Loading of uncoated tablets in the circulating coating pan for dedusting for 2-3 minutes with
a speed of 15rpm
¯
Spaying of coating solution onto the tablets for a certain period as specified in the Batch
Production Record (BPR) & subsequent drying by adjusting inlet and outlet air temperature
33
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Drying of coating over the tablets for 15minutes with same pan speed of 15rpm
¯
Film coated tablets
4.1.1.5.5.2. Process of Enteric Coating
For enteric coating the following procedure is used in the coating units of Incepta
Pharmaceutical Limited:
Mixing of polymer/s with the solvent system by the aid of a mechanical stirrer
¯
Transfer of colorant/s containing solution (previously prepared with the help of a
homogenizer) into the coating solution manufacturing vessel & mixing with the polymeric
solution
¯
Loading of uncoated tablets in the circulating coating panfor dedusting for 2-3 minutes with a
speed of15rpm
¯
Spaying of coating solution onto the tablets for the purpose of sub coating for some time as
specified in the Batch Production Record (BPR) & subsequent drying by adjusting inlet and
outlet air temperature
¯
Spaying of another coating solution onto the tablets for the purpose of enteric coating for
some time as specified in the Batch Production Record (BPR) & Subsequent drying by
adjusting inlet and outlet air temperature
¯
Drying of coating over the tablets for 15minutes with same pan speed of 15rpm
¯
Enteric-coated tablets
34
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
4.1.1.5.5.3. Machines Used in the Coating Unit for the Purpose of Both Film & Enteric
Coating
In each coating unit, the following machines are present;
Table 8: Machines Used in the Coating Unit
Name of the Machine Function
Manufacturing of Homogenous
Homogenizer
Solution of Colorants
Film cracking
Chipping
Orange peel
Picking
35
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
¯
Transfer of granules in the Drum or Double Cone Blender
¯
Transfer of Active ingredients & Glidants into the blender by passing through a sieve of mesh
size 20 & Colorants through 200 mesh screen
¯
Blending of the ingredients in the Drum (30 rpm) or Double Cone Blender (16 or 22 rpm) for
2-3 minutes as specified in the Batch Production Record (BPR) for a certain product
¯
Transfer of lubricants into the blender by passing through a sieve of mesh size 20
¯
Blending with the other ingredients in the same manner for 1 minute
¯
Uncoated Granules
¯
Coating
¯
Coated Granules
4.1.2. Capsule
Capsule is the solid unit dosage form of medication with a separate body & cap (Both are
gelatin shells). There are two types of capsules-Capsule with hard gelatin shell & Capsule
36
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
with soft gelatin shell. Hard capsules are filled with powders & pellets, whereas soft capsules
are filled with liquid or semisolid product.
According to British Pharmacopoeia,” Capsules are the solid dosage form in which the drug
is enclosed either in a hard or soft, soluble container or shell of a suitable form of gelatin”.
In this pharmaceutical industry filling (encapsulation), sealing and polishing (if required) of
capsules of hard gelatin shell are done during manufacturing, as the industry does not
manufacture any capsule shell.
The active is filled in the empty the hard gelatin capsule shell in the form of-
Powder
Pellets
There are 5 different sizes of empty hard gelatin capsule shells used in Incepta
Pharmaceuticals Ltd. for general production, which include-
37
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
¯
Encapsulation
For encapsulation of powder the following procedure is done with the help of Automatic
Capsule Filling Machine in the capsule filling units of the industry:
Blending
¯
Slugging
¯
Granulation
¯
Sieving
¯
Encapsulation
¯
Removal of caps of the shells
¯
Filling of powder
¯
Rejoining of caps of the shells
38
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Encapsulation
¯
Sorting of Capsules
¯
Polishing of Capsules
39
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
¯
Transfer of half portion of sucrose from step-1 into a double cone blender by passing through
a 20 mesh screen
¯
Transfer of all other excipients in the blender to blend for 30 minute
¯
Transfer the mix from the double cone blender by Passing through a 20 mash screen
40
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
41
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Syrups Suspension
42
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
43
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
44
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
4.2.7. Observation
Cleanliness & environment are strictly maintained.
Temperatures are quarterly maintained.
Water purity quarterly maintained
Purified water is used.
Microbial contamination is maintained.
Separate bottle washing and drying room.
All machines are operated according to standard operating procedure (SOP).
Machines are calibrated timely.
45
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Ampoules
Vials
¯
Ampoule washing
¯
Sterilization (in case of aseptically filled ampoules)
¯
Ampoule Filling (under laminar air flow)
¯
Ampoule Sealing
¯
Terminal Sterilization
¯
Ampoule Inspection
¯
Sealed Ampoules
46
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
47
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Particle Count
Table 13: Particle Cunt
Particle count at rest Particle count at operation Microbial growth
Class
(/m³) (/m³) (cfu)
0.5µ 5µ 0.5µ 5µ
180 3 1.1
Dry Heat Sterilization
220 2.5 1.1 Vials
(DHS)
260 1 1.1
Ampoules,
Steam Sterilization
121 0.5 1.1 Gloves, Filters,
/Autoclave
Gourmets
48
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Filling zone A 40
Sealing zone B 40
Filtration room B 30
49
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
50
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
IPA 70
Covers of Laminar air Before & after
Savlon 17.5
flow Production
Hypochlorite
1 Once a week
solution
51
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
52
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
53
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
54
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
55
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
A
4.4. Cephalosporin Products
According to cGMP regulations separate facility for Cephalosporin is required to prevent
cross contamination with other penicillin products or non-beta-lactum products. Unintended
exposure with Cephalosporin products may cause health concern to patients sensitive to
Cephalosporins.
Fully separated, well established and isolated manufacturing area only for
Cephalosporin.
Highly sophisticated HVAC system and AHU are used to condition, monitor and
supply clean air to the working zone.
Production floors and wall are covered with epoxy resin.
Incepta is the first national company in Bangladesh to build a dedicated state-of-the-art
Cephalosporin facility. Incepta currently produces tablets, capsules, powder for suspensions
and injectables in this facility.
Some of the high quality cephalosporin brands that are produced by this pioneer facility
include:
Cefadroxil – Adora
Cefepime – Ultrapime
Cefixime – Emixef
Cefpodoxime – Ximeprox
56
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Cefradine – Procef
Cefetamet – Tenafet
Ceftazidime – Sidobac
Ceftriaxone – Exephin
Cefuroxime – Kilbac
Cefotaxime – Cefotim
57
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
10 Dryer India
58
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
59
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
5. Packaging
Pharmaceutical packaging has to be carried out for the purpose of the safety of the
pharmaceutical preparations in order to keep them free from contamination, hinder microbial
growth, and ensure product safety through the intended shelf life for the pharmaceuticals.
Packaging is a critical tool in the pharmaceutical industry for product delivery and regulatory
compliance; many pharmaceutical companies will do all their packaging within a
contamination free environment or Cleanroom. Some common pharmaceutical packaging
techniques include foil and heat sealing; polyester and olefin package printing; polyethylene
and polypropylene printing; and flat bed die cutting.
The main purpose of using packaging material is to keep the pharmaceutical preparations safe
from any types of contamination.
Pharmaceutical products are mainly packed into two steps:
5.1. Primary Packaging
The packaging material with which the product always remains directly in contact is called
primary packaging. For example, blister packaging, bottle filling, foiling of capsule etc.
5.2. Secondary Packaging
After the primary packaging the products are packed with one or more packing material is
called secondary packing. For example, packing in outer carton or Shipper undergoes to
secondary packaging. Secondary packaging can be also classified into another two types.
These are:
a. Online Packaging
b. Offline Packaging
a. Online Packaging:
The packaging in which the primary packaging and secondary packaging are done
simultaneously is called online packaging.
b. Offline Packaging:
The packaging in which the primary packaging is done first and the secondary packaging is
done later, is called Offline Packaging.
The packaging materials are selected when they fulfill the following characteristics:
60
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
61
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Strip pack
Blister pack
Following materials are also included in packaging:
Label
Insert
Tape
Plastic cap
Dropper
plastic
62
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Quality Control
Quality Compliance
Quality Surveillance
The Quality Assurance department maintains product quality through cGMP & various
organized activities. This department is correlated with raw materials & packaging materials
sampling up to market compliance.
63
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Blend uniformity
Loss on drying (LOD) Identity
Appearance Odor
Disintegration
Dissolution
64
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Filling
Filling
Sealing
Sealing
Leak test
Weight variation
Presence of dust
Filled Volume
6.3. Documentation
Documentation of QA department includes the followings-
BPR Archival
65
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
66
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
67
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
68
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Assay
PH Alkalinity Printing
Stickiness Thickness Color
Toxicity Height Diameter
Density Breaking point Height
Alkalinity Volume
69
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Finished product
Process Validation
70
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Temperature: RT ± 20C
Relative humidity: 60 ± 5%
Accelerated stability test (AST): In accelerated stability products are kept for short life (3 or
6 months) in accelerated condition. Upon the stability over this condition, shelf life is
predicted.
Temperature: 40 ± 20C
Relative humidity: 75 ± 5%
If a product is stable over 1 year real time stability test, then 2 years of shelf life can be
predicted for the product.
If a product is stable over 3 months accelerated stability test, then 2 years of shelf life
can be predicted for the product.
If suppository is stable over 1 year real time stability test, then 1.5 years of shelf life
can be predicted for the products. Accelerated stability test can’t be done for
suppository, as it tends to melt on body temperature.
Stability Testing Parameters
Description Disintegration
Assay Dissolution
Viscosity Friability
pH Hardness
71
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
72
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
8. Microbiology Department
Microbiology is the study of microorganism. It is concerned with their form, structure,
reproduction, physiology, metabolism and classification. It includes the study of their
distribution in nature, their relationship to each other and to other living organisms, their
effects on human beings and on other animals and plants.
The Microbiology department at Incepta Pharmaceutical Limited works in association with
the QC department. The areas its analysis and different analytical methods are given below:
Table 21: The areas its analysis and different analytical methods
Tests Required for Tests
Microbial test
Filters
Sterility test
73
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
TSB 37 7
Microbial limit test
TGM 22 14
Limulus
Pyrogen test (LAL test) Amebocyte Lysate 37 14
(LAL) reagent
TSB 37 7
Sterility test
TGM 22 14
74
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Moist Heat
Sterilizer/autoclave
Particle counter
Incubator (Warmed)
Incubator (Cooled)
Microscope
Micropipettes
PH Meter
Conductivity Meter
75
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
9. Engineering Department
The Engineering Department guarantees proper production environment. The manufacturing
area of a Pharmaceutical plant demands different grades of cleanliness. Apart from particles,
moisture and temperature should also be within specification. Pharmaceutical plant also uses
different grades of water, steam lines, vacuum system and so on. All these utilities are
maintained by the Engineering Department.
9.1. Facilities
9.1.1. Electricity
The electricity supplies from 2 gas Generators of capacity 805 KW & 523 KW. the plant has
an electricity supply from Rural Electrification Board (REB) The plant has its own back up
secondary power system with 2 stand by Diesel generators, which provide 350KW &
252KW.
9.1.2. Central Air-conditioning System
The plant is fully air conditioned by central Fan Cooling Unit (FCU) system using 2 chillers
of capacity 350 tons and 250 tons, where ‘air compression’ ® ‘condensation’®
‘expansion’® ‘evaporation’®then again compression cycle is maintained
9.1.3. Air Handling Unit
There are 17 air-handling units including laminar airflow system. The individual air
conditioning unit is provided for separate section of the plants as per requirement, for
example, separate air handling units for sterile area, cooling area, washing area, production
area, administration area, Cephalosporin Building etc.
9.1.4. Air filtration System
This system is mainly used for sterile air for sterile area (Injection and Ointment) and
Cephalosporin Building.
9.1.5. Compressed Air
Compressed air is provided by central system with Two-compressor with speed of
6.98m3/min.
9.1.6. Boiler (Steam Generator)
The boiler or steam generator is of Shellmax Company. It has a capacity of 2.00 tons and
supply capacity of 3000 LBS/hr. Although the maximum used now about 2200 LBS/hr.
76
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Hot water
Purified water
DM water
77
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Circulation Booster
pump pump
Storage tank
(600L) Continuous
Purified Electro deionizer
Water
Loop
circulation Heat
pump exchanger
User Point
(25
78
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
79
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
80
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
Collection Tank
↓
Storage Tank
↓
Mixing & Cooling
↓
Neutralization
↓
Chemical Coagulation
↓
Biological Oxidation Tank
↓
Sedimentation & Separation of Sludge
↓
Sludge Thickener
↓
Filtration
↓
Discharge to Drain
Collection Tank: Commencing part, waste from different section enter here.
Storage Tank: Several blower pipes in this chamber. Mixing properties are different with
temp. as well.
Mixing & Cooling: Cooling tower is on paddle mixer used for mixing.
Neutralization: PH is controlled here.
Chemical Coagulation: Fe₂ (SO₄)₃, Al₂(SO₄)₃ etc use for coagulation.
Biological Oxidation Tank: Artificially Eco-system established. Blowing air helps to live
micro-organism.
Sedimentation & Separation of Sludge: The blanket of precipitations is skimmed off to
another tank and remaining solution is removed to pressure filter.
Sludge Thickener: After exceeding the required level of recycling, sludge passed through
thickening chamber.
Filtration: Filtration layer consists of sand rock which filters wet sludge to extract water rest
in it.
Discharge to Drain: Release to environment with the check of final load of effluent in it.
81
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
10. Conclusion
I feel very much proud on the completion of our in-plant training in The Incepta
Pharmaceuticals Ltd. as it is the leading pharmaceutical industry in Bangladesh. Its
contribution for the development of national economy is well known. I have gained cast
knowledge during this training period that will be definitely helping me in future.
Our academic curriculum would be insufficient if I was not here. But why I feel proud, the
cause is, first of all this is the fast-growing pharmaceutical industry in Bangladesh that
maintains “quality” first. Most important is that the company is assuring quality of all its
products and its company is doing its best to make medical development of human resources
of our country.
I would like to say that I have achieved my best knowledge here by having the opportunity to
have my training here. So, I am very much thankful to the Authority of Incepta
Pharmaceuticals Ltd.
I have learned many others thing from here, one of them was discipline. The Incepta
Pharmaceuticals Ltd. strictly follows the discipline, which is the key to their success and also
important in any organizational level. The officers here try heart and soul to lead the
company forward.
The two weeks in plant training has been completed successfully by the help of all the people
The Incepta Pharmaceuticals Ltd. My achievement during this training will eventually help
me in my professional life.
On behalf of our department and on my own behalf, I would like to express my hearties
thanks to Incepta Pharmaceuticals Ltd. I hope that such cooperation between the authority of
Incepta Pharmaceuticals Ltd. and the department of Pharmacy, Southeast University
Bangladesh will be strengthened day by day and will remain everlasting.
Finally, all best wishes to Incepta Pharmaceuticals Ltd.
82
Report On In-Plant Training At Incepta Pharmaceuticals Ltd.
11. References
www.inceptapharma.com
The Theory and practice of Industrial Pharmacy- Leon Lachman
http://en.wikipedia.org/wiki/Incepta_Pharmaceuticals
Assurance of Quality Pharmaceuticals- Dr.M. Shah Nawaz Khan
83